from a histologic standpoint , malignant fibrous histiocytomas and myogenic sarcomas appeared to benefit most with use of the use of the two-drug regimen used here , and the least favorable response was in liposarcomas and fibrosarcomas .
C1261473
sarcomas
C0016057
fibrosarcomas